TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18794650

Group type: EXPERIMENTAL
Intervention: Add-on of aripiprazole on a current regimen, wait for 4 weeks, and tapering of prior antipsychotics
Number of subjects: 53

Group type: COMPARATOR
Intervention: Add-on of aripiprazole and simultaneous tapering of prior antipsychotics
Number of subjects: 53
Study: 15878318

Group type: EXPERIMENTAL
Intervention: teriparatide 20 mug (TPTD20)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: teriparatide 40 mug (TPTD40)
Number of subjects: 558

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 558
Study: 11843044

Group type: EXPERIMENTAL
Intervention: Hemoccult‐II (H‐II) screening followed by colonoscopy
Number of subjects: 30967

Group type: EXPERIMENTAL
Intervention: Hemoccult‐II (H‐II) screening
Number of subjects: 30967
Study: 10073816

Group type: EXPERIMENTAL
Intervention: Preoperative clinical algorithm for cardiac risk stratification
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium‐201 scintigraphy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Presurgical myocardial revascularization
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Vascular surgery with perioperative intensive care treatment
Number of subjects: 320
Study: 7479623

Group type: EXPERIMENTAL
Intervention: On-sale outlets
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Off-sale outlets
Number of subjects: 887
Study: 2254672

Group type: EXPERIMENTAL
Intervention: Doxium 500 (1.5 g, 3 capsules/day)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Doxium 500
Number of subjects: 225
Study: 7016973

Group type: EXPERIMENTAL
Intervention: Dicyclomine hydrochloride 40 mg 4 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31562118

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control
Number of subjects: 655
Study: 29697595

Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 230

Group type: COMPARATOR
Intervention: Testing as usual
Number of subjects: 230
Study: 26986563

Group type: EXPERIMENTAL
Intervention: Institutional delivery service utilization
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Predictors of institutional delivery
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Antenatal care service
Number of subjects: 957
Study: 24833692

Group type: EXPERIMENTAL
Intervention: Evidence-based information booklet including overdetection, breast cancer mortality reduction and false positives
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control information booklet (including mortality reduction and false positives only)
Number of subjects: 970

Group type: EXPERIMENTAL
Intervention: Evidence-based information booklet
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control information booklet
Number of subjects: 970
Study: 22956531

Group type: EXPERIMENTAL
Intervention: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Marsh model
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Schnider model
Number of subjects: 66
Study: 20491772

Group type: EXPERIMENTAL
Intervention: Excimer laser (EL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clobetasol propionate (CP)
Number of subjects: 13
Study: 18797455

Group type: EXPERIMENTAL
Intervention: CAPIRI (capecitabine plus irinotecan)
Number of subjects: 267

Group type: COMPARATOR
Intervention: CAP (capecitabine single agent)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: CAPIRI (for Val-allele carriers)
Number of subjects: 267

Group type: COMPARATOR
Intervention: CAPIRI and CAP (Ile/Ile genotype)
Number of subjects: 267
Study: 16042878

Group type: EXPERIMENTAL
Intervention: 0.1 mg entecavir
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: 0.5 mg entecavir
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 11819181

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg po bid
Number of subjects: 18
Study: 10574107

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg (100 ml) given by slow intravenous infusion 90-60 minutes before operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 20
Study: 9051513

Group type: EXPERIMENTAL
Intervention: Implantation using a forceps
Number of subjects: 100

Group type: COMPARATOR
Intervention: Implantation using an injector
Number of subjects: 100
Study: 1649422

Group type: EXPERIMENTAL
Intervention: Combined therapy (40 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Immunomodulating therapy with Sintomodulin (20 patients)
Number of subjects: 60
Study: 6842340

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31781298

Group type: EXPERIMENTAL
Intervention: miR‐1, miR‐133a, and miR‐499
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: LVEF
Number of subjects: 122
Study: 29426362

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing three kinds of bactericidal ingredients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Test dentifrice
Number of subjects: 30
Study: 26827977

Group type: EXPERIMENTAL
Intervention: Elipar LED unit, cured for 10 seconds
Number of subjects: 40

Group type: COMPARATOR
Intervention: VALO LED unit, cured for 3 seconds
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In-vitro bond strengths for Elipar LED unit
Number of subjects: 40

Group type: COMPARATOR
Intervention: In-vitro bond strengths for VALO LED unit
Number of subjects: 40
Study: 25497747

Group type: EXPERIMENTAL
Intervention: Esmolol (500mcg/kg bolus followed by 100mcg/kg/min infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 60
Study: 22435980

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage using lavender oil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 20353312

Group type: EXPERIMENTAL
Intervention: MPH-ER
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 18517090

Group type: EXPERIMENTAL
Intervention: Enhanced Treatment (ET)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Minimal Treatment (MT)
Number of subjects: 281
Study: 16014055

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 1560
Study: 12757209

Group type: EXPERIMENTAL
Intervention: Proguanil 100 mg BID plus sulfamethoxazole 1,000 mg BID for 7 days
Number of subjects: 25
Study: 10347332

Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg IV dofetilide over 30 minutes
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg IV dofetilide
Number of subjects: 96
Study: 7894098

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied twice daily for 16 days (phase 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 5th or 7th day (phase 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 10th day (phase 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 14th day (phase 2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single application of Clobetasol propionate (CP)
Number of subjects: 12
Study: 1657248

Group type: EXPERIMENTAL
Intervention: Heparin or low molecular weight heparin (LMWH; Fragmin)
Number of subjects: 194
Study: 6406438

Group type: EXPERIMENTAL
Intervention: Bupropion (450 to 750 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amitriptyline (75 to 225 mg/day)
Number of subjects: 40
Study: 30308615

Group type: EXPERIMENTAL
Intervention: IBBR with ADM
Number of subjects: 135

Group type: COMPARATOR
Intervention: IBBR without ADM
Number of subjects: 135
Study: 28379650

Group type: EXPERIMENTAL
Intervention: Postoperative eye patching for approximately 18 hours
Number of subjects: 132

Group type: COMPARATOR
Intervention: Eye shield (control group)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Postoperative eye patching
Number of subjects: 132
Study: 26370148

Group type: EXPERIMENTAL
Intervention: Rehabilitation gaming device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual follow-up treatment
Number of subjects: 15
Study: 24384803

Group type: EXPERIMENTAL
Intervention: Computerized counseling
Number of subjects: 240

Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Computerized counseling (among those with detectable virus at baseline)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Assessment only (Control) (among those with detectable virus at baseline)
Number of subjects: 240
Study: 21992993

Group type: EXPERIMENTAL
Intervention: 0.1% timolol maleate gel
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.5% timolol aqueous solution
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.5% timolol maleate gel
Number of subjects: 43
Study: 19357643

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: pyridostigmine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17473776

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 17530933

Group type: EXPERIMENTAL
Intervention: HMB (3 g.d(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HMBCr (12 g.d(‐1) with 3 g HMB, 3 g Cr, 6 g carbohydrates)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15061303

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.5 per cent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preservative-free ketorolac tromethamine 0.5 per cent
Number of subjects: 0
Study: 10962110

Group type: EXPERIMENTAL
Intervention: Atrial septal defect (ASD) group
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 21
Study: 9062158

Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy and total parenteral nutrition (TPN)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Salvage chemotherapy alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Chemotherapy (unspecified)
Number of subjects: 21
Study: 8458110

Group type: EXPERIMENTAL
Intervention: Low dose duteplase (0.16-0.29 MIU/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Middle dose duteplase (0.30-0.41 MIU/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High dose duteplase (0.43-0.74 MIU/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All doses of duteplase
Number of subjects: 75
Study: 3463754

Group type: EXPERIMENTAL
Intervention: Premix (conventional alloy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dispersalloy (blended non-gamma 2 amalgam)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sybraloy (spherical alloy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tytin (spherical alloy)
Number of subjects: 12
Study: 30321689

Group type: EXPERIMENTAL
Intervention: RT + 9 weekly cycles of docetaxel + 3 years of androgen deprivation therapy (arm B)
Number of subjects: 132

Group type: COMPARATOR
Intervention: RT + 3 years of luteinizing hormone-releasing hormone analogues (arm A)
Number of subjects: 132
Study: 27450646

Group type: EXPERIMENTAL
Intervention: Sesamin capsules; 200 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo capsules; 200 mg/day starch
Number of subjects: 48
Study: 25957183

Group type: EXPERIMENTAL
Intervention: e‐intervention 1 (access to intervention during pregnancy and control at postpartum)
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: e‐intervention 2 (access to intervention during pregnancy and postpartum)
Number of subjects: 1722

Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 1722
Study: 23423673

Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 21106433

Group type: EXPERIMENTAL
Intervention: Segmental rotational grade V manipulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: McKenzie's lumbar extension exercises (EE)
Number of subjects: 50
Study: 19410978

Group type: EXPERIMENTAL
Intervention: Egg group (640 mg/d additional dietary cholesterol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (0 mg/d additional dietary cholesterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 16675507

Group type: EXPERIMENTAL
Intervention: Sparkling wine (30 g of ethanol/day for 28 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: White wine (20 g of ethanol/day for 28 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Red wine (20 g of ethanol/day for 28 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cohort study on Mediterranean diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Gin (30 g of ethanol/day for 28 days)
Number of subjects: 72
Study: 15138203

Group type: EXPERIMENTAL
Intervention: ALA-PDT (single dose of 100 J/cm² at four hours) - PDT100 (n=13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ALA-PDT (fractionated dose of 20 and 100 J/cm² at one and four hours) - PDT20+100 (n=13)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Argon Plasma Coagulation (APC) at a power setting of 65 W in two sessions (n=14)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Histological examination at 12 months for PDT100 (n=11)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Histological examination at 12 months for PDT20+100 (n=10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Histological examination at 12 months for APC (n=12)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Side effects after PDT
Number of subjects: 40
Study: 11479245

Group type: EXPERIMENTAL
Intervention: Nebivolol/bendrofluazide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol/bendrofluazide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nebivolol/bendrofluazide and Atenolol/bendrofluazide
Number of subjects: 12
Study: 9757191

Group type: EXPERIMENTAL
Intervention: Post-operative chemotherapy and pre-operative induction chemotherapy in patients with stage IIIA N2 disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with thoracic radiotherapy (TRT) in unresectable, locally advanced NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timely combination of TRT and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic agents as radiosensitizers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of TRT and new agents in unresectable, locally advanced NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery following induction chemo-radiotherapy in locally advanced NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer chemotherapy for advanced NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cancer chemotherapy in metastatic NSCLC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents (irinotecan, paclitaxel, docetaxel, vinorelbine, gemcitabine) along with combination chemotherapy
Number of subjects: 0
Study: 8058236

Group type: EXPERIMENTAL
Intervention: Terodiline, 25 mg twice daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 3132181

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms bid
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms bid
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enprostil 7 micrograms bid
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31583943

Group type: EXPERIMENTAL
Intervention: G‐CSF support during EC and docetaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy without G‐CSF support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: G‐CSF use
Number of subjects: 0
Study: 30526016

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted exercise group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional self-exercise group
Number of subjects: 84
Study: 28578799

Group type: EXPERIMENTAL
Intervention: Mobile-bearing TAA through anterior approach
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Fixed-bearing TAA through lateral approach
Number of subjects: 217

Group type: COMPARATOR
Intervention: Control group (non-arthritic tibiotalar joint)
Number of subjects: 217
Study: 26503276

Group type: EXPERIMENTAL
Intervention: Insecticide-treated curtains for dengue prevention
Number of subjects: 1333
Study: 23651146

Group type: EXPERIMENTAL
Intervention: Memory rehabilitation intervention groups
Number of subjects: 31

Group type: COMPARATOR
Intervention: Self-help control group
Number of subjects: 31
Study: 21293252

Group type: EXPERIMENTAL
Intervention: BIS-monitored patients
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Cumulative duration of BIS values less than 45
Number of subjects: 1473
Study: 19623435

Group type: EXPERIMENTAL
Intervention: Trazodone (5HT2a/c antagonist)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no trazodone)
Number of subjects: 20
Study: 16510641

Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Inpatient admission
Number of subjects: 92
Study: 15213587

Group type: EXPERIMENTAL
Intervention: Evidence-based pharmacotherapy algorithm
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 64
Study: 11360134

Group type: EXPERIMENTAL
Intervention: Selenium and zinc supplementation (Se 200 microg/day and Zn 21 mg/day) for 50 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 60
Study: 9340698

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg daily)
Number of subjects: 30
Study: 8369892

Group type: EXPERIMENTAL
Intervention: Home exercises
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hydrotherapy (twice weekly for 6 weeks in addition to home exercises)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hydrotherapy
Number of subjects: 47
Study: 3789649

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (20-50 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Indacrinone (50-100 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Indacrinone plus amiloride (50-100 mg and 5-10 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (during 4-week run-in period)
Number of subjects: 24
Study: 30103772

Group type: EXPERIMENTAL
Intervention: C21 (an angiotensin type 2 receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan (an angiotensin receptor blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline/C21 followed by Candesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Saline/C21 monotherapy
Number of subjects: 0
Study: 29354973

Group type: EXPERIMENTAL
Intervention: Ginger-separated moxibustion at Baliao points combined with Bushen Huoxue formula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bushen Huoxue formula alone
Number of subjects: 50
Study: 26259675

Group type: EXPERIMENTAL
Intervention: Uncoated mini-tablets
Number of subjects: 151

Group type: COMPARATOR
Intervention: Syrup
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 151
Study: 23103075

Group type: EXPERIMENTAL
Intervention: Consolidation period of 5 weeks (Group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Consolidation period of 14 weeks (Group 2)
Number of subjects: 18
Study: 21147783

Group type: EXPERIMENTAL
Intervention: Rocuronium (0.3 mg kg⁻¹)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alfentanil (20 µg kg⁻¹)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (i.v. saline 0.5 ml kg⁻¹)
Number of subjects: 75
Study: 18509206

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17196051

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 575

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575

Group type: COMPARATOR
Intervention: Lamotrigine vs. Placebo
Number of subjects: 575

Group type: COMPARATOR
Intervention: Lithium vs. Placebo
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Lamotrigine vs. Lithium
Number of subjects: 575
Study: 15018018

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 microg/g ointment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg/g cream
Number of subjects: 41
Study: 11115258

Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 581
Study: 9402292

Group type: EXPERIMENTAL
Intervention: 0.4% (w/v) HSA
Number of subjects: 413

Group type: COMPARATOR
Intervention: 8% (v/v) FCoS
Number of subjects: 413
Study: 8219654

Group type: EXPERIMENTAL
Intervention: Insulin treatment; hemoglobin A1c before: 11.3 +/- 2.8, after: 7.0 +/- 1.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment; hemoglobin A1c before: 11.3 +/- 1.4, after: 7.3 +/- 0.9
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; carnitine levels did not differ from control group and did not change significantly during the observed period.
Number of subjects: 0
Study: 2442322

Group type: EXPERIMENTAL
Intervention: COPA (cyclophosphamide, vincristine, prednisone, and doxorubicin)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: COPA + Bleo (cyclophosphamide, doxorubicin, prednisone, vincristine, and bleomycin)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: CAP-BOP (cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone)
Number of subjects: 332

Group type: COMPARATOR
Intervention: COPA
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: COPA + Bleo
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: CAP-BOP
Number of subjects: 332